Prostate Cancer Clinical Trial End Points: “RECIST”ing a Step Backwards

Prostate cancer clinical trial end points: "RECIST"ing a step backwards.

PURPOSE To relate clinical issues to the clinical manifestations of prostate cancers across disease states using the eligibility and outcome criteria defined by Response Evaluation Criteria in Solid Tumors (RECIST). EXPERIMENTAL DESIGN The manifestations of prostate cancer that characterize localized, recurrent, and metastatic disease were considered using the eligibility criteria for trials ...

End points and clinical trial design in pulmonary arterial hypertension.

New and emerging therapies might provide benefit in patients with pulmonary arterial hypertension. Their efficacy and safety will be compared with existing combination therapies in randomized clinical trials. Appropriate end points for these trials need to be identified: these will include exercise testing, the composite end point of time to clinical worsening, and hemodynamic markers, includin...

Validation of novel imaging methodologies for use as cancer clinical trial end-points.

The success or failure of a clinical trial, of any phase, depends critically on the choice of an appropriate primary end-point. In the setting of phases II and III cancer clinical trials, imaging end-points have historically, and continue presently to play a major role in determining therapeutic efficacy. The primary goal of this paper is to discuss the validation of imaging-based markers as en...

step by step progress towards genetic knowledge of prostate cancer

Clinical and Pathological Features of Iraqi Patients with Prostate Cancer

Background: The clinical pathological features were detected by measuring the prostatic acid phosphatase (PAP) activity according to the stages and grades of prostate cancer. We also explored the relationship between the disease and age with family history among the patients. Methods: Data were collected from direct interview and from the patient’s records. Blood samples that collected before ...